subject: Technologies And Global Markets Of Biological Therapies For Cancer [print this page] Biological Therapies for Cancer: Technologies and Global Markets
This report analyzes in detail the biological cancer markets. This report includes products in this market, and detailed analyses of markets and competitive environments, cancer markets in newly emerging therapeutics, and biosimilars and their impact on the market. The report includes information about significant products, key players, issues and trends, current market status of cancer biotherapeutics, strengths, weaknesses, opportunities and threats facing various cancer biotherapeutics already on the market, major issues involved in the research and development (R&D) of more effective cancer therapeutics, and new cancer therapeutics in development and in clinical trials. ( http://www.bharatbook.com/detail.asp?id=145048&rt=Biological-Therapies-for-Cancer-Technologies-and-Global-Markets.html )
REASONS FOR DOING THE STUDY
The rise in the number of cancer diagnosis, wider access, and affordability of treatment regimes in developing countries will stimulate growth in the world cancer therapies market. It is the second-leading cause of death in the U.S. and according to the American Cancer Society (ACS), 50% of men and 30% of women will develop some form of cancer in their lifetime. Newer biotherapeutics have emerged in the past few years that have had a significant impact on cancer treatment and health. The market for biological therapies in cancer treatment will nearly double in the next 5 years and reach more than $50 billion in the next 5 to 10 years. The demand for newer and innovative oncology drugs will continue to grow as healthcare systems worldwide emphasize cancer detection and treatment. This report covers the current market status of cancer biotherapeutics, strengths, weaknesses, various cancer biotherapeutics already on the market, major issues involved in the R&D of more effective cancer therapeutics, and new cancer therapeutics in development and in clinical trials
Highlights :
* Coverage of biological products in development, in clinical trials, currently marketed, and late-stage-development biologic cancer products
* Analysis of market trends, citing data for 2008, estimates for 2009, and projections, including 5-year compound annual growth rates (CAGRs), through 2014
* Discussion of drug classes with special focus on cancer treatments, including growth hormones, erythropoietin, colony stimulating factors and interleukin-2 drugs, interferons/interferons kinases, monoclonal antibodies, and vaccines
* Company profiles and patent analyses.
For more information kindly visit : http://www.bharatbook.com/detail.asp?id=145048&rt=Biological-Therapies-for-Cancer-Technologies-and-Global-Markets.html
